Hydroxyurea lowers total medical costs for pediatric sickle cell anemia

09/3/2013 | DoctorsLounge.com

Despite having higher outpatient costs, hydroxyurea treatment for children with sickle cell anemia had a 21% lower total estimated annual cost than placebo, according to a study in the journal Pediatrics. The hydroxyurea group had fewer hospitalizations compared with the placebo group, but both had similar lengths of stay.

View Full Article in:

DoctorsLounge.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD